ASCO GI 2021 | First-line regorafenib 80mg/day with pembrolizumab in advanced HCC

Anthony B. El-Khoueiry, MD, Keck School of Medicine of USC, Los Angeles, CA, discusses highlights from the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium 2021, including the results of an ongoing Phase Ib study of regorafenib 80 mg/day plus pembrolizumab for first-line treatment of advanced hepatocellular carcinoma (HCC). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).